[Effect of PC-cell derived growth factor shRNA on estrogen dependent of estrogen receptor negative breast cancer cell lines].
OBJECTIVE
To analyze the relationship between estrogen dependence of breast cancer cells and expression level of PC-cell derived growth factor (PCDGF) and investigate the possibility of practicing endocrine therapy in estrogen receptor negative breast cancer.


METHODS
Expression level of PCDGF mRNA was detected by fluorescence quantitative polymerase chain reaction and cell growth curve was drawn by cell count kit-8 method, then analyzed the relationship between the expression of PCDGF and dependence of estrogen. PCDGF shRNA vector was constructed and transfected into breast cancer cell lines (MCF-7 and MDA-MB-231) using Lipofectamin 2000, examined and compared the changes of estrogen dependence between the two cell lines.


RESULTS
PCDGF was expressed in most breast cancer cell lines, and the growth dependence of estrogen was higher in the cells with high-expressing PCDGF than those with low-expressing PCDGF. Expression of PCDGF could be inhibited by transfected shRNA into MCF-7 and MDA-MB-231 (inhibition rates were 81.1% and 86.7% respectively), inhibition of the expression of PCDGF could lead to higher growth dependence of estrogen, and the dependence of MDA-MB-231 was increased much more than MCF-7(P < 0.05).


CONCLUSIONS
The expression level of PCDGF is higher in estrogen receptor negative breast cancer than in estrogen receptor positive breast cancer. Inhibiting the expression of PCDGF could reverse resistance of endocrine therapy especially to estrogen receptor negative breast cancer.
Shi
Lan
L
Breast and Thyroid Surgery Center, Union Hospital of Huazhong University of Science and Technology, Wuhan 430022, China.
Song
Hai-Ping
HP
Liu
Chun-Ping
CP
Huang
Tao
T
D001943:Breast Neoplasms / Q000235:genetics / Q000378:metabolism / Q000473:pathology; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects; D019008:Drug Resistance, Neoplasm; D004967:Estrogens / Q000494:pharmacology*; D005260:Female; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D036341:Intercellular Signaling Peptides and Proteins / Q000235:genetics* / Q000378:metabolism; D000077153:Progranulins; D034622:RNA Interference; D034741:RNA, Small Interfering / Q000235:genetics; D011960:Receptors, Estrogen / Q000378:metabolism; D014162:Transfection
D004967:Estrogens; C492314:GRN protein, human; D036341:Intercellular Signaling Peptides and Proteins; D000077153:Progranulins; D034741:RNA, Small Interfering; D011960:Receptors, Estrogen